Related references
Note: Only part of the references are listed.The Human GLP-1 Analogs Liraglutide and Semaglutide: Absence of Histopathological Effects on the Pancreas in Nonhuman Primates
Carsten F. Gotfredsen et al.
DIABETES (2014)
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
T. A. Wadden et al.
INTERNATIONAL JOURNAL OF OBESITY (2013)
Clinical Efficacy and Safety of Once-Weekly Glucagon-Like Peptide-1 Agonists in Development for Treatment of Type 2 Diabetes Mellitus in Adults
Maria Tzefos et al.
ANNALS OF PHARMACOTHERAPY (2012)
ELEVATED AMYLASE AND LIPASE LEVELS IN PATIENTS USING GLUCAGONLIKE PEPTIDE-1 RECEPTOR AGONISTS OR DIPEPTIDYL-PEPTIDASE-4 INHIBITORS IN THE OUTPATIENT SETTING
Howard M. Lando et al.
ENDOCRINE PRACTICE (2012)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Juris J. Meier
NATURE REVIEWS ENDOCRINOLOGY (2012)
Effects of Multiple Doses of Albiglutide on the Pharmacokinetics, Pharmacodynamics, and Safety of Digoxin, Warfarin, or a Low-Dose Oral Contraceptive
Mark Bush et al.
POSTGRADUATE MEDICINE (2012)
Incretin-based therapies - review of the physiology, pharmacology and emerging clinical experience
J. H. Martin et al.
INTERNAL MEDICINE JOURNAL (2011)
Treatment With Liraglutide-a Once-Daily GLP-1 Analog-Does Not Reduce the Bioavailability of Ethinyl Estradiol/Levonorgestrel Taken as an Oral Combination Contraceptive Drug
Lisbeth V. Jacobsen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Chrysi Koliaki et al.
Diabetes Therapy (2011)
Liraglutide
Daniel J. Drucker et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone
Hartmut Blode et al.
CONTRACEPTION (2008)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Share Paper
